These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 20685900)

  • 21. Sleep disturbances and depression: a challenge for antidepressants.
    Lam RW
    Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S25-9. PubMed ID: 16436937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Agomelatine, an innovative pharmacological response to unmet needs.
    Le Strat Y; Gorwood P
    J Psychopharmacol; 2008 Sep; 22(7 Suppl):4-8. PubMed ID: 18753276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
    Goodwin GM; Emsley R; Rembry S; Rouillon F;
    J Clin Psychiatry; 2009 Aug; 70(8):1128-37. PubMed ID: 19689920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Agomelatine in depressive disorders: its novel mechanisms of action.
    Srinivasan V; Zakaria R; Othman Z; Lauterbach EC; Acuña-Castroviejo D
    J Neuropsychiatry Clin Neurosci; 2012; 24(3):290-308. PubMed ID: 23037643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mechanism, efficacy, and tolerability profile of agomelatine.
    MacIsaac SE; Carvalho AF; Cha DS; Mansur RB; McIntyre RS
    Expert Opin Pharmacother; 2014 Feb; 15(2):259-74. PubMed ID: 24328686
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Agomelatine: the first "melatoninergic" antidepressant].
    Bánki MC
    Neuropsychopharmacol Hung; 2006 Oct; 8(3):105-12. PubMed ID: 17211046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of antidepressants in clinical practice: focus on agomelatine.
    McAllister-Williams RH; Baldwin DS; Haddad PM; Bazire S
    Hum Psychopharmacol; 2010 Mar; 25(2):95-102. PubMed ID: 20196187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of agomelatine in previously-treated depressed patients.
    Kasper S; Hajak G
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):814-21. PubMed ID: 23820051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A benefit-risk assessment of agomelatine in the treatment of major depression.
    Howland RH
    Drug Saf; 2011 Sep; 34(9):709-31. PubMed ID: 21830835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression.
    De Berardis D; Fornaro M; Serroni N; Campanella D; Rapini G; Olivieri L; Srinivasan V; Iasevoli F; Tomasetti C; De Bartolomeis A; Valchera A; Perna G; Mazza M; Di Nicola M; Martinotti G; Di Giannantonio M
    Int J Mol Sci; 2015 Jan; 16(1):1111-30. PubMed ID: 25569089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Agomelatine as chronopsychopharmaceutics restoring circadian rhythms and enhancing resilience to stress: a wishfull thinking or an innovative strategy for superior management of depression?
    Jakovljević M
    Psychiatr Danub; 2011 Mar; 23(1):2-9. PubMed ID: 21448091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine.
    Montgomery SA; Kasper S
    Int Clin Psychopharmacol; 2007 Sep; 22(5):283-91. PubMed ID: 17690597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials.
    Koesters M; Guaiana G; Cipriani A; Becker T; Barbui C
    Br J Psychiatry; 2013 Sep; 203(3):179-87. PubMed ID: 23999482
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addressing circadian rhythm disturbances in depressed patients.
    Lam RW
    J Psychopharmacol; 2008 Sep; 22(7 Suppl):13-8. PubMed ID: 18753278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.
    Lôo H; Hale A; D'haenen H
    Int Clin Psychopharmacol; 2002 Sep; 17(5):239-47. PubMed ID: 12177586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
    De Berardis D; Di Iorio G; Acciavatti T; Conti C; Serroni N; Olivieri L; Cavuto M; Martinotti G; Janiri L; Moschetta FS; Conti P; Di Giannantonio M
    CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):119-32. PubMed ID: 20874703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
    Udristoiu T; Dehelean P; Nuss P; Raba V; Picarel-Blanchot F; de Bodinat C
    J Affect Disord; 2016 Jul; 199():6-12. PubMed ID: 27054610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel melatonin-based therapies: potential advances in the treatment of major depression.
    Hickie IB; Rogers NL
    Lancet; 2011 Aug; 378(9791):621-31. PubMed ID: 21596429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Agomelatine in depression.
    Smeraldi E; Delmonte D
    Expert Opin Drug Saf; 2013 Nov; 12(6):873-80. PubMed ID: 24033095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review.
    Pompili M; Serafini G; Innamorati M; Venturini P; Fusar-Poli P; Sher L; Amore M; Girardi P
    World J Biol Psychiatry; 2013 Aug; 14(6):412-31. PubMed ID: 23530731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.